Does Estrogen Therapy Have Cardiovascular Benefit in Early Postmenopause?
Using a single-center, randomized, double-blind, placebo-controlled trial (RCT), the authors randomized one group of women to receive oral 17ß-estradiol (1 mg/day) while the other group received placebo. Women in the estrogen group who had a uterus also received progesterone (45 mg). The primary outcome measure was rate of change of intima-media wall thickness of the common carotid artery (CIMT) to assess atherosclerosis progress. Women were stratified into 2 groups – those who were < 6 years since menopause (early postmenopause) and those > 10 years since menopause (late postmenopause).
After a median of 5 years, in women receiving estrogen the following outcomes were observed:
In the early postmenopause group, rate of carotid artery atherosclerosis progression was significantly lower (P=0.007)
In the late postmenopause group, there was no difference in atherosclerosis progression
Progesterone did not alter this effect
No difference was found in coronary artery atherosclerosis with estrogen use using CT angiography
There was no difference in adverse events such as breast cancer or myocardial infarction – although these were not primary outcome measures
There have been conflicting studies regarding cardiovascular benefits with the use of estrogen and progesterone following menopause. One hypothesis suggested that this is a reflection of timing – if greater than 10 years after menopause, the vasculature and hormone receptors may no longer be sufficiently functional to result in any benefit. The authors in this study (NEJM, 2016), used a well designed trial to show that hormone replacement therapy may be beneficial in protecting against cardiovascular disease
Oral estradiol therapy is associated with decreased progression to atherosclerosis (using carotid artery measurements) but only if therapy is started within 6 years of menopause
The differing response based on time from menopause may explain the conflicting results in multiple studies
The study was not designed to assess the effects of estrogen on new coronary artery lesions
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan